6:12 PM
 | 
Dec 10, 2012
 |  BC Extra  |  Clinical News

Boehringer presents volasertib Phase II AML data

Boehringer Ingelheim GmbH (Ingelheim, Germany) presented interim data from the Phase II portion of a Phase I/II trial of volasertib to treat newly diagnosed acute myelogenous leukemia (AML). Intravenous injections of...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >